Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID
· Real-Time Price · USD
0.32
-0.01 (-2.17%)
At close: May 01, 2025, 3:59 PM
0.33
4.46%
After-hours: May 01, 2025, 07:06 PM EDT
-2.17% (1D)
| Bid | 0.31 |
| Market Cap | 22.63M |
| Revenue (ttm) | 566K |
| Net Income (ttm) | -26.43M |
| EPS (ttm) | -0.37 |
| PE Ratio (ttm) | -0.86 |
| Forward PE | -0.72 |
| Analyst | Buy |
| Ask | 0.34 |
| Volume | 291,584 |
| Avg. Volume (20D) | 391,890 |
| Open | 0.34 |
| Previous Close | 0.33 |
| Day's Range | 0.31 - 0.34 |
| 52-Week Range | 0.24 - 3.43 |
| Beta | 0.44 |
About OVID
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule...
Industry Biotechnology
Sector Healthcare
IPO Date May 5, 2017
Employees 23
Stock Exchange NASDAQ
Ticker Symbol OVID
Website https://www.ovidrx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for OVID stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 842.21% from the latest price.
Stock ForecastsNext Earnings Release
Ovid Therapeutics Inc. is scheduled to release its earnings on May 13, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
10 months ago
-76%
Ovid Therapeutics shares are trading lower after T...
Unlock content with
Pro Subscription
